Coherus Biosciences | CHRS

Coherus Biosciences traded at $8.49 this Friday February 3rd, decreasing $0.47 or 5.25 percent since the previous trading session. Looking back, over the last four weeks, Coherus Biosciences lost 13.98 percent. Over the last 12 months, its price fell by 31.09 percent. Looking ahead, we forecast Coherus Biosciences to be priced at 8.07 by the end of this quarter and at 7.30 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
8.49
Daily Change
-5.25%
Yearly
-31.09%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
LG Chem 674,000.00 -2,000.00 -0.30% -0.59%
Fujifilm 6,839.00 42.00 0.62% -10.74%
AbbVie 145.20 0.36 0.25% 3.24%
Acadia Pharmaceuticals 19.83 -0.08 -0.40% -15.97%
Akebia Therapeutics 0.99 0.10 10.79% -45.82%
ALKERMES 27.35 -0.27 -0.98% 15.35%
Alnylam Pharmaceuticals 233.37 3.62 1.58% 60.48%
Amgen 245.17 -1.36 -0.55% 10.38%
Amarin 1.89 -0.06 -3.08% -48.36%
Baxter International 46.68 -0.33 -0.70% -46.17%
Biogen 283.63 -3.89 -1.35% 28.03%
Bluebird Bio 6.65 0.02 0.30% -2.35%
BioMarin Pharmaceutical 112.20 -0.64 -0.57% 26.59%
Bristol-Myers Squibb 74.45 1.68 2.31% 14.56%
Coherus Biosciences 8.49 -0.47 -5.25% -31.09%
Endo International 0.10 -0.001 -0.72% -96.89%
Gilead Sciences 84.50 3.11 3.82% 32.24%
Horizon Pharma 109.68 -0.11 -0.10% 18.51%
Ironwood Pharmaceuticals 11.40 -0.14 -1.21% 3.17%
Jazz Pharmaceuticals 155.64 -0.76 -0.49% 10.43%
Eli Lilly 339.08 8.38 2.53% 39.96%
Merck & Co 102.94 -0.52 -0.50% 31.03%
Myriad Genetics 19.96 -0.82 -3.95% -20.64%
Pacira 41.86 -1.21 -2.81% -34.96%
Pfizer 44.06 -0.28 -0.63% -16.87%
Perrigo 37.20 0.15 0.40% 1.39%
PTC Therapeutics 48.04 0.68 1.44% 14.14%
Regeneron Pharmaceuticals 783.13 31.93 4.25% 25.71%
Revance Therapeutics 34.92 -0.35 -0.99% 161.38%
Sarepta Therapeutics 119.00 -1.25 -1.04% 62.77%
Teva Pharmaceutical Industries Ltd 3,605.00 -6.00 -0.17% 32.88%
Vertex Pharmaceuticals 301.02 -2.76 -0.91% 24.41%
Xencor 36.49 1.35 3.84% 14.03%
Zoetis 167.80 -3.20 -1.87% -15.91%

Indexes Price Day Year
USND 12007 -193.86 -1.59% -14.83%
US400 2707 -19.14 -0.70% 3.21%

Coherus Biosciences
Coherus BioSciences, Inc. is a commercial stage biotherapeutics company. The Company is focused on the biosimilar and immuno-oncology market primarily in the United States. The Company’s pipeline includes the four categories product candidates, Oncology pipeline, Immunology pipeline, Ophthalmology pipeline and Small Molecule pipeline. Oncology pipeline includes Toripalimab, an anti-PD-1 antibody; UDENYCA (pegfilgrastim-cbqv); CHS-305, a bevacizumab (Avastin) biosimilar. Immunology pipeline includes CHS-1420, an anti-TNF product candidate, as an adalimumab (Humira) biosimilar. Ophthalmology pipeline includes CHS-201, a ranibizumab (Lucentis) biosimilar. CHS-201, a ranibizumab (Lucentis) biosimilar. Small Molecule pipeline includes CHS-131, an oral, small-molecule drug candidate. CHS-131 is a once-daily oral drug candidate for non-alcoholic steatohepatitis (NASH) and other metabolic conditions.